Skip to content
value.today

Inhibikase Therapeutics, Inc.

IQT.F
$14 Mlast known market cap, Dec 2022 — no current value
Compare
World rank
—
no current market cap
Revenue
—
For year ending December-2025
Net income
$-48 M
SEC filing
Employees
—

Inhibikase Therapeutics, Inc. in brief

Inhibikase Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Georgia, USA. Its last known market value was $14 M (December 2022); there is no current figure. Milton Werner is its chief executive. Its shares trade under the symbol IQT.F (Frankfurt).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

Inhibikase Therapeutics, Inc. timeline

2 events, 2018–2021
  1. 2018
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2021
  4. 💰
    Record revenue of $3 million
    FY2021, the highest of the 4 years on record.

Events of Inhibikase Therapeutics, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$10 M$19 M$29 M$39 M

World rank over time

▼ down 3,062 places since 2022
2022-01-07: #27514#27,51420222022-12-25: #30576#30,5762022

Rank in USA: #5,071 (Jan 2022) · #5,440 (Dec 2022)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
—
Operating margin
—
Return on equity
-27.9%
Liabilities / assets
4.6%
Net debt
$-9M
Revenue growth
+116.7%
R&D / revenue
5238.5%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2020: revenue $1M, net income $-3M$1MFY20Fiscal year ending Dec 2021: revenue $3M, net income $-15M$3MFY21Fiscal year ending Dec 2022: revenue $0M, net income $-18M$0MFY22Fiscal year ending Dec 2023: revenue $0M, net income $-19M$0MFY23Fiscal year ending Dec 2024: revenue —, net income $-28M—FY24Fiscal year ending Dec 2025: revenue —, net income $-48M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-52M$-48M—
Dec 2024——$-29M$-28M—
Dec 2023$0M+116.7%$-20M$-19M-7319.2%
Dec 2022$0M-96.1%$-18M$-18M-15041.7%
Dec 2021$3M+342.9%$-15M$-15M-477.1%
Dec 2020$1M—$-3M$-3M-407.1%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-28M$0M$-28M$-0.49—
Dec 2024$-19M$0M$-19M$-1.16—
Dec 2023$-18M$0M$-18M$-3.16—
Dec 2022$-17M$0M$-18M$-4.28—
Dec 2021$-14M$0M$-14M$-0.81—
Dec 2020$-1M——$-0.35—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-12M—Dec ’24Three months to Mar 2025: revenue —, net income $-14M—Mar ’25Three months to Jun 2025: revenue —, net income $-10M—Jun ’25Three months to Sep 2025: revenue —, net income $-12M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-13M—Dec ’25Three months to Mar 2026: revenue —, net income $-16M—Mar ’26Three months to Jun 2026: revenue —, net income $-20M—Jun ’26Three months to Sep 2026: revenue —, net income $-20M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-20M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Inhibikase Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-52 M
Net income
$-48 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$181 M
Total liabilities
$8 M
Total equity
$173 M

As of December-2025

Mutual funds holding Inhibikase Therapeutics, Inc.#

67 funds hold shares worth $29 M. Since their previous reports 48 added shares and 10 sold, buying $6 M net.
Mutual funds holding Inhibikase Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.3.76 M$8 M—<0.01%+9.9%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors3.01 M$6 M—<0.01%+23%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC1.32 M$3 M—<0.01%+25%Jul 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors1.11 M$2 M—0.02%+34%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.1.06 M$2 M—<0.01%+16%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.547,192$1 M—<0.01%+83%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors406,711$1 M—0.05%+51%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC421,326$1 M—<0.01%+121%May 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.294,004$1 M—<0.01%+25%Jul 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC236,794$0 M—<0.01%+36%Jun 30, 2026
🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC215,750$0 M—<0.01%−8.5%Jun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC161,780$0 M—<0.01%+27%Jul 31, 2026
🇺🇸 JPMorgan Small Cap Value FundJ.P. Morgan Investment Management Inc.171,152$0 M—0.03%−5.7%Jun 30, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC169,113$0 M—0.02%+40%Jun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC142,061$0 M—<0.01%+34%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC143,459$0 M—<0.01%+174%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC113,097$0 M—<0.01%+107%May 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation90,100$0 M—<0.01%+88%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.75,662$0 M—0.01%+88%May 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.63,298$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC57,994$0 M—<0.01%+25%Jul 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.56,309$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.52,148$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC56,270$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC42,523$0 M—<0.01%no changeJun 30, 2026
🇺🇸 JPMorgan Small Cap Value PortfolioBrighthouse Investment Advisers, LLC42,101$0 M—0.03%−14%Jun 30, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust47,634$0 M—<0.01%newMay 31, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company44,328$0 M—<0.01%+84%May 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.36,600$0 M—<0.01%no changeJun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC36,124$0 M—<0.01%−1.1%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC40,273$0 M—<0.01%+33%May 31, 2026
🇺🇸 Small Cap Value FundThe Variable Annuity Life Insurance Company34,863$0 M—0.02%newMay 31, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC27,096$0 M—<0.01%+293%Jul 31, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC28,770$0 M—<0.01%+35%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS27,823$0 M—<0.01%+36%Jun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC27,600$0 M—<0.01%no changeJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC27,404$0 M—0.03%+45%Jun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC20,052$0 M—<0.01%no changeJun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.19,063$0 M—<0.01%+28%Jun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC18,480$0 M—<0.01%+26%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.18,305$0 M—<0.01%+58%Jun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC15,963$0 M—<0.01%+53%Jun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC14,217$0 M—<0.01%+107%Jul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC12,924$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.11,504$0 M—<0.01%+9.0%Jul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management11,018$0 M—<0.01%+78%Jun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC9,682$0 M—<0.01%+93%Jun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC9,323$0 M—<0.01%+43%Jun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS8,689$0 M—<0.01%no changeJul 31, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS8,278$0 M—<0.01%newJul 31, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC8,105$0 M—<0.01%+124%Jul 31, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC8,555$0 M—0.01%+46%Jun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC7,660$0 M—<0.01%+432%Jun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC7,660$0 M—<0.01%+432%Jun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION7,800$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.6,942$0 M—<0.01%+92%May 31, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.6,410$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC5,345$0 M—<0.01%+30%Jun 30, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC4,440$0 M—<0.01%−49%Jun 30, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC5,044$0 M—<0.01%+93%May 31, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.3,479$0 M—<0.01%+71%Jun 30, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC3,987$0 M—<0.01%+6.9%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC3,944$0 M—<0.01%+5.4%May 31, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC2,749$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC2,425$0 M—<0.01%newJun 30, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC2,165$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.52$0 M—<0.01%+108%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 67 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Inhibikase Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$3.0 M
1 purchase, 1 insider
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$3.0 M
open market only
Insiders on file
10
since
$3.0 M$0Oct 2024: bought $2.7 M (3 trades), sold $0 (0 trades)Oct 24Nov 2025: bought $3.0 M (1 trades), sold $0 (0 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
Inhibikase Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Dennis N. BermanDirectorOption exercise+21,854$1.260$28 K21,854Form 4
filed RA Capital Healthcare Fund LP10% ownerOtherindirect-18.03 M——6.97 MForm 4
filed Amit MunshiDirectorDisposal to the company-19,089——38,176Form 4
filed Christopher CabellPresident & Head of R&DDisposal to the company-338,282——676,564Form 4
filed Vincent AurentzDirectorDisposal to the company-255,299——510,596Form 4
filed Frank M. Sands10% ownerBuy+2.07 M$1.450$3.0 M13.02 MForm 4
filed Amit MunshiDirectorGrant or award+57,265——57,265Form 4
filed Arvind KushDirectorBuy+145,000$1.370$199 K145,000Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Inhibikase Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
19.4 M
14.8% of shares · 28.59 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-1.14 reverse split

Fails to deliver

  • : 2,441 shares at $1.67
  • : 3,955 shares at $1.62
  • : 1,495 shares at $1.59
  • : 9,082 shares at $1.65
  • : 3,776 shares at $1.91

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Inhibikase Therapeutics, Inc. scorecard#

Passes 1 of the 8 checks that could be worked out. Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.49 vs -1.16Diluted EPS -0.49 in fiscal 2025 against -1.16 the year before (report's currency).
    • ✗Net income higher than five years earlier-$48 M-$48 M in fiscal 2025 against -$3 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$48 MNet income -$48 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-36.0%-36.0% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities21.7×Current ratio 21.70 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year314.6%Diluted shares up 314.6% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Inhibikase Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Inhibikase Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue—00.30.13.10.7
Research and development30171412110.9
Selling, general and administrative24116.76.26.52.6
Total costs and expenses52292018183.5
Operating income−52−29−20−18−15−2.8
Interest expense and finance costs————0.00.0
Net interest income3.71.11.10.1−0.0—
Income before tax−0.0−0.0————
Income tax00————
Net income attributable to shareholders−48−28−19−18−15−2.8
Earnings per share, basic-0.49-1.16-3.16r-4.28r-0.81-0.35
Earnings per share, diluted-0.49-1.16-3.16r-4.28r-0.81-0.35
Shares, weighted average (basic)98246.0r4.2r18—
Shares, weighted average (diluted)98246.0r4.2r188.2
Balance sheet
Cash and cash equivalents17998r9.2r7.24114
Short-term investments40414.1160—
Other current assets0.30.80.7r0.21.50.1
Current assets1809814244215
Property, plant and equipment00.00.10.20—
Right-of-use (leased) assets00.10.20.30—
Total assets1819915254215
Accounts payable1.20.90.61.21.11.7
Debt due within a year00.10.20.10—
Current liabilities8.33.73.43.74.14.7
Lease liabilities (non-current)——0.10.2——
Total liabilities8.33.73.53.94.15.0
Retained earnings−143−94−67−48−30r15r
Shareholders' equity173951121389.8
Total liabilities and equity1819915254215
Shares outstanding132696.24.2r2510
Cash-flow statement
Share-based compensation158.10.50.51.50.6
Cash from operating activities−28−19−18−17−14−1.1
Capital expenditure−0.00−0.0−0.20—
Cash from investing activities2.1−3712−160—
Shares issued1081038.5000.0
Cash from financing activities1081038.4−0.24115
Report10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Inhibikase Therapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$30.6 M
Mark Iwicki, Milton Werner
Other top executives, average
$6.5 M
the CEO earned 4.7× this
$100 invested is now
$161
Inhibikase Therapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Mark Iwicki, Milton Werner$30.6 M$29.7 M$6.5 M$161
2024Milton Werner$8.0 M$7.6 M$790 K$256

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Inhibikase Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling

Auditor changed 1 · Directors and officers 6 · Material agreement 3 · Agreement ended 1 · Unregistered share sale 2 · Bylaws or fiscal year changed 2 · Shareholder vote 3 · Results announced 8

Inhibikase Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Auditor changed8-K
Results announced8-K
Unregistered share sale8-K
Directors and officersBylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officersMaterial agreementUnregistered share sale8-K
Directors and officers8-K
Bylaws or fiscal year changedShareholder vote8-K
Agreement ended8-K
Directors and officersMaterial agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

1 acquisitions, $7 M paid where reported

Businesses it acquired

Acquisitions by Inhibikase Therapeutics, Inc.
AcquiredAcquisition dateCompletionPriceStakeSource
CorHepta PharmaceuticalsFeb 2025—$7 M—Annual report

Private share sales · funding history

Private share sales of Inhibikase Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2023$4 MPrivate placement after listing$2 to $10 million1optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Inhibikase Therapeutics, Inc.#

1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $212 K a year.

Certified, FY2026
1
#1,916 among companies on value.today
Worker positions
1
Median wage offered
$212 K
a year, full-time
Applications filed
1
Inhibikase Therapeutics, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Associate Director, Clinical Operations (00108024)Natural Sciences Managers1$212 K

Where: New York, NY 1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Inhibikase Therapeutics Inc

How Inhibikase Therapeutics, Inc. compares in Biotechnology

  • Revenue growth116.7% · higher than 84% of 438

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Inhibikase Therapeutics, Inc.🇺🇸$14 M——+116.7%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Dec 25, 2022 (last known)
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Inhibikase Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Inhibikase Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Inhibikase Therapeutics, Inc.? Suggest a correction